Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Synapton NDA is nonapprovable, FDA says

Nov. 24, 1998

Substituted heteroaromatic 5-ht1f agonists in development at Lilly as antimigraine agents

Nov. 24, 1998

Novel CRF1-specific ligands claimed by Neurogen

Nov. 24, 1998

Pyridazine and phthalazine derivatives from SmithKline Beecham for CNS, neurological disorders

Nov. 24, 1998

Dual 5-HT reuptake inhibitor/5-HT1A antagonist discussed at neuroscience meeting

Nov. 24, 1998

Sch-50971: a novel histamine H3 agonist with antimigraine and sedative effects in preclinical models

Nov. 23, 1998

MK-0869 effective and well tolerated in patients with major depressive disorder

Nov. 23, 1998

Cytogen and Berlex finalize supply agreement with DuPont for Quadramet

Nov. 23, 1998

Pharmacia & Upjohn's reboxetine now available in Spain

Nov. 23, 1998

Neuroprotective effects and mode of action of Ono-2506 detailed at recent meeting

Nov. 20, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...